Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

NCT04537156 PHASE3 ACTIVE_NOT_RECRUITING

This phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD., in healthy women aged 18-45 years old.

Details

Lead sponsor	Xiamen University
Phase	PHASE3
Status	ACTIVE_NOT_RECRUITING
Enrolment	9327
Start date	Sat Sep 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Cervical Intraepithelial Neoplasia
• Cervical Cancer
• Condylomata Acuminata

Interventions

• Nonavalent HPV vaccine
• Bivalent HPV vaccine

Countries

China